IOVAIOVANCE BIOTHERAPEUTICS, INC.同业对比
IOVANCE BIOTHERAPEUTICS, INC. 与Biological Products, (No Diagnostic Substances)的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 (Biological Products, (No Diagnostic Substances))| 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IOVA本股 | $1.9B#8 | — | 2.7x#4 | 7.3x#5 | 60.6%#6 | -5.1%#7 | -153.1%#8 | -54.2%#8 | — | — | 60.6%#8 | — |
| TARS | $2.6B#1 | — | 7.6x#8 | 5.8x#4 | 146.7%#2 | 43.1%#5 | -15.7%#5 | -18.9%#4 | -22.2%#3 | — | 50.1%#9 | — |
| KOD | $2.5B#2 | — | 22.2x#10 | — | — | -30.5%#10 | — | -205.1%#11 | — | — | 499.5%#2 | — |
| VCEL | $2.4B#3 | 96.3x#2 | 6.4x#7 | 8.6x#6 | 16.5%#10 | 59.4%#3 | 4.0%#4 | 4.5%#2 | 4.0%#2 | 7#1 | 29.4%#10 | — |
| BCRX | $2.2B#4 | — | — | 2.6x#2 | 94.1%#3 | 396.9%#1 | 39.0%#2 | — | — | — | 10.6%#12 | — |
| COAG | $2.1B#5 | — | — | — | — | — | — | — | — | — | — | — |
| ADMA | $2.0B#6 | 12.8x#1 | 5.2x#6 | 4.0x#3 | 19.6%#8 | -25.7%#9 | 37.5%#3 | 37.6%#1 | 34.3%#1 | 5#2 | -54.8%#15 | — |
| RVMDW | $1.9B#7 | — | 1.3x#1 | — | — | -88.5%#12 | — | -75.4%#10 | — | — | 4673.9%#1 | — |
| RXRX | — | — | — | — | 26.9%#7 | -39.1%#11 | -867.9%#10 | -62.9%#9 | -174.7%#5 | — | -43.8%#13 | — |
| TSHA | $1.7B#9 | — | 7.8x#9 | 170.0x#10 | 17.3%#9 | -22.1%#8 | -1130.6%#11 | -51.4%#6 | — | — | 120.6%#5 | — |
| MAZE | $1.5B#10 | — | 4.4x#5 | 9.0x#7 | — | -351.0%#14 | -85.3%#7 | -38.4%#5 | -78.6%#4 | — | 82.7%#6 | — |
| VIR | $1.5B#11 | — | 1.8x#2 | 21.9x#9 | -7.6%#11 | 16.1%#6 | -699.2%#9 | -53.9%#7 | — | — | 77.1%#7 | — |
| GLUE | $1.3B#12 | — | 2.5x#3 | 10.5x#8 | 63.5%#5 | 46.9%#4 | -43.8%#6 | -7.4%#3 | — | — | 221.7%#4 | — |
| NVAX | $1.2B#13 | — | — | 1.1x#1 | 64.7%#4 | 334.8%#2 | 40.3%#1 | — | — | — | 13.0%#11 | — |
| INBX | $1.2B#14 | — | — | 932.9x#11 | 550.0%#1 | -108.3%#13 | -10386.5%#12 | — | — | — | 280.0%#3 | — |
| VOR | $1.2B#15 | — | — | — | — | -495.3%#15 | — | — | — | — | -49.0%#14 | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 数据构建于 2026-08-04。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议